trending Market Intelligence /marketintelligence/en/news-insights/trending/t-ptqn9qulo1nheo756zng2 content esgSubNav
In This List

Therapix Biosciences director resigns

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet

Blog

Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback

Blog

Infographic: The Big Picture 2023 Issuer & Investor Relations Outlook


Therapix Biosciences director resigns

Mark Groussman has resigned as a director of Therapix Biosciences Ltd.

Groussman's resignation was not related to any disagreement with the board on any matter relating to the operations, policies or practices, according to Therapix.

Tel Aviv, Israel-based Therapix Biosciences is a specialty clinical-stage pharmaceutical company that develops drugs based on cannabinoid molecules.